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I N H E R I T E D B O N E M A R R O W FA I L U R E S Y N D R O M E S
James Joseph Southern Maine Community College, Spring 2021
Fanconi anemia is a rare but serious blood disorder that prevents bone marrow from making enough new
blood cells for body to perform normal functional activities. It can cause to bone marrow (the sponge-like
tissue in the bones), to make abnormal blood cells. It is an inherited autosomal recessive caused by
mutation in the genes known as the FA genes, which provides instruction to repair certain types of DNA
damage.

Abstract
The inherited bone marrow failure syndromes are heterogeneous group of rare genetic
disorders characterized by bone marrow failure, congenital anomalies, and cancer
predisposition. This includes disorders associated with pancytopenia, such as fanconi
anemia and dyskeratosis congenita, as well as disorders with predominantly, but not
exclusively, single lineage cytopenias.
These syndromes are associated with mutations in 33 genes, and this has led to further
understanding of hematopoiesis and how this is disrupted in patients with bone marrow
failure. Other fundamental biological pathways were examined in patients, such as the
DNA repair-fa/BRCA pathway. Fanconi anemia/BRCA is a human tumor suppressor gene
also known as a caretaker gene and is responsible for repairing damage DNA or destroy
cells if DNA cannot be repaired. Another pathway examined was the telomere
maintenance of dyskeratosis congenita, an inherited bone marrow failure syndrome
characterized clinically by the triad of abnormal nails, reticular skin pigmentation, that has
been found to have x-linked recessive, autosomal dominant and autosomal recessive
subtypes. There is also a mutated gene in x-linked DC (DKC1) which encodes a highly
conserved nucleolar protein called dyskerin. Dyskerin associates with the H/ACA (human
anti-chimeric antibody) a class of small nucleolar RNA in small nucleolar
ribonucleoprotein particles (snornp), which are important in guiding the conversion of
uracil to pseudouracil during the maturation of ribosomal RNA.

Myelodysplastic syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone
marrow do not mature, cannot form healthy blood cells.
Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized clinically by the
triad of abnormal nails, reticular skin pigmentation, and oral leukoplakia, and associated with very high
risks of developing aplastic anemia, myelodysplastic syndrome, leukemia, and solid tumors. Patients have
very short germline telomeres, and approximately half have mutations in one of six genes encoding proteins
that maintain telomere function.
Fig.2. Image adapted from Hematol Oncol Clin North Am. 2018 Aug; 32(4): 643–655.

Immune mediated selection pressure drives the expansion of HSPCs
(Hematopoietic stem and progenitor cells) with context to specific growth
advantage.

Severe congenital neutropenia is characterized by profound peripheral neutropenia. Individual with the congenital
disorder usually present with recurrent, life-threatening infections in infancy. Bone marrow examination usually
reveals a maturation arrest in the myeloid lineage. The disease can progress to myelodysplasia and leukemia, usually
with acquisition of secondary mutations including mutations in the granulocyte colony-stimulating factor receptor.
Heterozygous mutations in the neutrophil elastase gene (ELA2) have been demonstrated in the majority of patients.
These mutations are thought to lead to the accumulation of a non-functional protein which in turn triggers an
unfolded protein response leading to maturational arrest. The original family described by Kostmann, had autosomal
recessive severe congenital neutropenia, which has been shown to be associated with biallelic mutations in
the HAX1 gene predicted to lead to defects in cell death. Mutations in other genes (GFI1, WASP) are also known to be
associated with severe congenital neutropenia, demonstrating genetic heterogeneity

Interconnected pathways that cause bone
marrow failure

This poster will review recent literature about the mutations that are most directly
associated with this rare genetic disorder.
Bone marrow failure (BMF) disorders are characterized by presentation with pancytopenia
or single lineage cytopenias. Although acquired aplastic anemia (AA) is the most common
BMF disease at all ages, children and adults may have an inherited BMF (IBMF) disease
that must be diagnosed if present, because this is critically important not only for treatment
choices but also to monitor for progression to myelodysplastic syndrome (MDS) or acute
myeloid leukemia (AML). MDS and AML occur with increased frequency through
acquisition of somatic mutations in medically treated patients with acquired AA but have a
much greater likelihood in patients with germline.
This reviewed article presents the cases of pancytopenia associated with acquired aplastic
anemia and bone marrow failure syndromes. These disorders has been differentiated for the
presentation of treatment decisions. Identification of new inherited germline cell diseases
as a result of genetic testing intervention in patients presented with inherited bone marrow
failure disorder was made possible. In patients, evidence as shown that many individuals
with this disorder may appear to be normal with fewer or no symptoms in clinical settings.
The prognostic value of somatic mutation may vary in different stages of individual level
of advancement of the disease. The proliferative defect observed in inherited bone marrow
failure syndrome can be reversed using hematopoietic stem cells, which may still furtherly
develop somatic mutations and may progress to myelodysplastic syndrome or acute
myeloid leukemia.

Fig.3 Image adapted from Hematol Oncol Clin North Am. 2018 Aug; 32(4): 643–655.

The Image above fig. depicts the pathways affected in inherited bone
marrow failure and MDS/AML predisposition syndromes. The abnormal
chromosomal breakage, if present mutation are seen in one of the genes 14.
This also shows presence of a mutation in the DCK1, TERT or TERC genes
16, by increased erythrocyte adenosine deaminase (eada) activity and/or by
mutation in the RPS19, RPS24, RPS17, RPL5, RPL11 or RPL35A genes
18. Presence of neutropenia associated with exocrine pancreatic
insufficiency and, if possible, by mutation in the SBDS gene 6.
An onset of thrombocytopenia, typical bone marrow findings, and
mutations in the thrombopoietin receptor (cmpl) gene 7.
In AA, number of tests demonstrated that untreated AA leads to the
apoptosis of CD3+, inhibits CD34+ cell which is crucial for HSPCs
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Bone marrow failure syndromes are associated with dysfunctional hematopoiesis that may
drive a strong selective pressure that favors mutated hematopoietic stem and progenitor cells
with enhanced fitness. as seen in the fig. above (red) some mutations may result in leukemic
transformation, others may enable clonal expansion due to functional complementation of
disease specificity to cellular defects (green). The latter may involve biological pathways that
are distinct from leukemic transformation and not associated with elevated risk of progression
to MDS or AML.
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Fig.4. Image adapted from Ferrata Storti Foundation

Genes known to be mutated in the different pathways that lead to bone marrow failure are
highlighted in the interconnected pathways. Genes mutated in the telomere maintenance pathway
are circled in purple. The mutated gene and other interconnecting proteins are: RP ribosomal
protein; FANC, Fanconi anemia complementation group; DKC1, dyskeratosis congenita 1,
dyskerin; NOP10, nucleolar protein 10 homolog; NHP2, non-histone ribonucleoprotein 2
homolog; GAR1, glycine and arginine rich riboncleoprotein 1 homolog; TERF1, telomeric
repeat binding factor 1; TERF2, telomeric repeat binding factor 2; TINF2, TERF1-interacting
nuclear factor 2; TERF2IP, TERF2 interacting protein (RAP1); POT1 protection of telomeres 1
homolog; TPP1, TIN2 interacting protein 1 (ACD, adrenocortical dysplasia homolog); PINX1,
PIN2 (TERF1) interacting protein; ATM, ataxia telangiectasia mutated; M/R/N:
MRE11/RAD50/NBS1, meiotic recombination 11 homolog A/radiation resistance 50
homolog/Nijmegen breakage syndrome 1; ATR, ataxia telangiectasia and Rad3 related (Seckel
syndrome); BRCA1, breast cancer 1. BRIP1, BRCA1 interacting protein C-terminal helicase 1;
PALB2, partner and localizer of BRCA2.

Lastly, numbers of evidence shows that individual presented with bone marrow failure
were suspected to have inherited bone marrow failure by the combination of various
factors observed at young age, low birth weight, macrocytosis and high levels of
hemoglobin F. However, most individual shows a normal chromosomal breakage test,
normal telomere length, and no mutations in SBDS or c-mpl genes. Furthermore, The
BRCA1/2 majorly play a huge role in the regulation of telomere maintenance and a
mutation in this gene may result in BMFS, in addition, there are still some ongoing
research been tested.

